The ISSCR commends the U.S. Food and Drug Administration (FDA) for its policy direction and enforcement efforts, announced today, to provide “bright lines and appropriate oversight” when regulating stem cell treatments and regenerative medicine. The agency reported its enforcement actions against clinics in California and Florida offering unproven stem cell therapies, and announced pending policy and regulatory efforts against these practices.